Trial Profile
A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess AZD2014 in Combination With Novel Anti-Cancer Agents in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (INHIBITOR Study)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Vistusertib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms INHIBITOR
- Sponsors AstraZeneca
- 14 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 May 2016 New trial record